Abstract: The invention provides methods of diagnosing autism spectrum disorders (ASD) by identification of altered metabolic characteristics in such subjects. By measuring concentrations of metabolites in a sample, such as a blood or plasma sample, from a subject, changes in the activity of specific metabolic pathways can be identified. In turn, ASD subjects can be classified based on metabolic defects. Thus, the methods allow healthcare professionals to provide patient-specific guidance on a course of treatment for individuals who have or are at risk of developing ASD.

Abstract: The invention provides methods for predicting whether compounds are cardiotoxic by analyzing their effects on the ratios of concentrations of metabolites in cultured heart muscle cells.

Abstract: The invention provides methods of diagnosing autism spectrum disorders (ASD) by analyzing ratios of concentrations of selected amine containing compounds in a sample, such as a blood sample, from a subject. Based on the discovery that specific amine containing compounds and their ratios are dysregulated in patients with ASD, these metabotypes or subtypes of metabolism have the potential to diagnose earlier and suggest more precise treatment based on the metabolism of the individual. The invention provides methods of analyzing amine containing compounds and ratios in a test subject and determining whether the test subject has or is at risk of developing an ASD by comparing ratios from the test subject to ratios from subjects diagnosed with a neurodevelopmental disorder such as ASD who share a common profile of metabolism which is not found in the majority of typically developing subjects.

Abstract: The invention provides biomarker profiles of metabolites and methods for screening chemical compounds including pharmaceutical agents, lead and candidate drug compounds and other chemicals using human stem-like cells (hSLCs) or lineage-specific cells produced therefrom. The inventive methods are useful for testing toxicity, particularly developmental toxicity and detecting teratogenic effects of such chemical compounds. Specifically, a more predictive developmental toxicity model, based on an in vitro method that utilizes both hSLCs and metabolomics to discover biomarkers of developmental toxicity is disclosed.

Abstract: This invention provides methods and biomarkers for diagnosing autism by identifying cellular metabolites differentially produced in autistic patient samples versus non-autistic controls. Methods for identifying a unique profile of metabolites present or secreted in brain tissue, cerebrospinal fluid, plasma, or biofluids of autistic samples are described herein. The individual metabolites or a pattern of secreted metabolites provides metabolic signatures of autism, which can be used to provide a diagnosis thereof.

Abstract: This present invention provides rapid, reproducible, biomarker-based screening methods for the developmental toxicity testing of compounds. The methods are designed to identify the exposure level at which a test compound perturbs metabolism in a manner predictive of developmental toxicity. In particular, the perturbation of two metabolites, ornithine and cystine, is measured, wherein a ratio of the fold change in ornithine to the fold change in cystine of less than or equal to about 0.88 is indicative of the teratogenicity of a test compound.

Abstract: This invention provides methods and biomarkers for diagnosing autism by identifying cellular metabolites differentially produced in autistic patient samples versus non-autistic controls. Methods for identifying a unique profile of metabolites present of secreted in brain tissue, cerebrospinal fluid, plasma, or biofluids of autistic samples are described herein. The individual metabolites or a pattern of secreted metabolites provide metabolic signatures of autism, which can be used to provide a diagnosis thereof.

Abstract: This invention provides methods and biomarkers for diagnosing autism by identifying cellular metabolites differentially produced in autistic patient samples versus non-autistic controls. Methods for identifying a unique profile of metabolites present of secreted in brain tissue, cerebrospinal fluid, plasma, or biofluids of autistic samples are described herein. The individual metabolites or a pattern of secreted metabolites provide metabolic signatures of autism, which can be used to provide a diagnosis thereof.

Abstract: A motor controller coupled to a motor is described. The motor controller includes a wireless communication device and a computing device coupled to the wireless communication device. The computing device is configured to communicatively couple with a client computing device using the wireless communication device, wirelessly receive at least one setting from the client computing device, and operate the motor pursuant to the at least one setting, to move liquid in an aquatic environment.

Abstract: The invention provides biomarker profiles of metabolites and methods for screening chemical compounds including pharmaceutical agents, lead and candidate drug compounds and other chemicals using human stem-like cells (hSLCs) or lineage-specific cells produced therefrom. The inventive methods are useful for testing toxicity, particularly developmental toxicity and detecting teratogenic effects of such chemical compounds. Specifically, a more predictive developmental toxicity model, based on an in vitro method that utilizes both hSLCs and metabolomics to discover biomarkers of developmental toxicity is disclosed.

Abstract: The invention provides biomarker profiles of metabolites and methods for screening chemical compounds including pharmaceutical agents, lead and candidate drug compounds and other chemicals using human stem-like cells (hSLCs) or lineage-specific cells produced therefrom. The inventive methods are useful for testing toxicity, particularly developmental toxicity and detecting teratogenic effects of such chemical compounds. Specifically, a more predictive developmental toxicity model, based on an in vitro method that utilizes both hSLCs and metabolomics to discover biomarkers of developmental toxicity is disclosed.

Abstract: This invention provides methods and biomarkers for diagnosing autism by identifying cellular metabolites differentially produced in autistic patient samples versus non-autistic controls. Methods for identifying a unique profile of metabolites present of secreted in brain tissue, cerebrospinal fluid, plasma, or biofluids of autistic samples are described herein. The individual metabolites or a pattern of secreted metabolites provide metabolic signatures of autism, which can be used to provide a diagnosis thereof.

Abstract: The invention provides biomarker profiles of metabolites and methods for screening chemical compounds including pharmaceutical agents, lead and candidate drug compounds and other chemicals using human stem-like cells (hSLCs) or lineage-specific cells produced therefrom. The inventive methods are useful for testing toxicity, particularly developmental toxicity and detecting teratogenic effects of such chemical compounds. Specifically, a more predictive developmental toxicity model, based on an in vitro method that utilizes both hSLCs and metabolomics to discover biomarkers of developmental toxicity is disclosed.

Abstract: A gas discharge lamp power supply having a base, a pair of opposed side walls extending from the base, and opposed first and second end walls extending from the base between the opposed side walls. The first end wall has a sloped wall extending angularly between the side walls, and two input terminals are mounted on the sloped wall. In another embodiment, the power supply has a control with a nonvolatile memory for storing an error code in response to a detected fault condition, thereby permitting the error code to be displayed upon power being removed from and then, subsequently reapplied.

Abstract: The invention provides methods for measuring cellular response to ionization radiation (IR). The invention also provides a plurality of diagnostic and prognostic cancer biomarkers for assessing cellular response to IR.

Abstract: A gas discharge lamp power supply having a base, a pair of opposed side walls extending from the base, and opposed first and second end walls extending from the base between the opposed side walls. The first end wall has a sloped wall extending angularly between the side walls, and two input terminals are mounted on the sloped wall. In another embodiment, the power supply has a control with a nonvolatile memory for storing an error code in response to a detected fault condition, thereby permitting the error code to be displayed upon power being removed from and then, subsequently reapplied.

Abstract: An alignment device and related systems and methods for aligning at least one apparatus with respect to a surface of a tissue. The alignment device comprises a tissue interface member suitable for positioning on the surface of the tissue and mating with the apparatus to maintain alignment of the apparatus during an operation of the apparatus. The alignment device is useful to align various apparatus that are part of a continuous analyte monitoring system.

Abstract: An enclosure for an electrical connection between two high-voltage cables that includes an electrically nonconductive separator integral with a mounting base for receiving the high-voltage cables. An electrically nonconductive tubular cover extends over the electrical connection and the high-voltage cables and is releasably attached to the base. The separator has at least two resiliently mounted fingers, and the electrically nonconductive cover extends over the fingers to depress and move the fingers into contact with the high-voltage cables, thereby securing the high-voltage cables in the mounting base. The high-voltage cables are extended beyond the mounting base a distance equal to a desired spacing separating the electrical connection between the high-voltage cables and an electrical conductor associated with the mounting base. The tubular cover is transparent so that the electrical connection joining the high-voltage cables can be visually inspected through the cover.

Abstract: A transformer control circuit which includes a ground fault detection circuit that detects ground fault currents in the transformer secondary and delivers a ground fault detection signal to the primary circuit. This circuit derives power from the secondary winding and transmits the ground fault detection signal through an optical isolation barrier, thus avoiding the use of an auxiliary transformer. The ground fault detection circuit further includes safety features for detecting whether AC power is being supplied without earth ground being connected, and/or whether there is an undesired electrical connection between a transformer output connection and earth ground, which would defeat the ground fault detection circuit.

Abstract: Apparatus and methods for noninvasively measuring cardiovascular system parameters. According to a first preferred embodiment, the apparatus generates a time varying electrical voltage waveform having voltages corresponding to systolic and diastolic arterial pressures of the subject, the parameters being modelled by a lumped element electric circuit model analogous to the living subject's cardiovascular system, said circuit model including a systolic capacitor analogous to arterial compliance during systole, said apparatus comprising means for computing the value of said systolic capacitor from a measurement of an elapsed time between two voltage levels within a portion of said voltage waveform corresponding to systole, according to a predetermined criteria; and means for computing at least one said cardiovascular system parameter from said capacitor value. According to a second embodiment, a time-varying systolic arterial compliance is measured by measuring an arterial pulse pressure waveform.